Breaking Finance News

BofA Merrill downgraded Cardiovascular Systems (NASDAQ:CSII) from Neutral to Underperform in a report released today.

Yesterday Cardiovascular Systems (NASDAQ:CSII) traded -1.10% lower at $31.61. The company’s 50-day moving average is $30.19 and its 200-day moving average is $30.13. The last closing price is up 1.08% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 307,141 shares of the stock traded hands, up from an average trading volume of 237,641

BofA Merrill has downgraded Cardiovascular Systems (NASDAQ:CSII) from Neutral to Underperform in a report released on 06/21/2017.

See Chart Below

Cardiovascular Systems (NASDAQ:CSII)

Cardiovascular Systems has a 52 week low of $21.29 and a 52 week high of $33.11 The company’s market cap is currently $0.

In addition to BofA Merrill reporting its stock price target, a total of 6 brokers have issued a report on the company. The average stock price target is $16.50 with 2 brokers rating the stock a strong buy, 3 brokers rating the stock a buy, 1 broker rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Cardiovascular Systems (NASDAQ:CSII)

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.